Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder in which ageing, altered lifestyle, genetic, and environmental factors contribute to producing insulin resistance in target tissues, leading to hyperglycaemia. Previous studies have reported lower levels of Interleukin-10 (IL-10), an anti-inflammatory cytokine in T2DM patients. However, the knowledge regarding its receptor (IL-10R) expression changes in T2DM is unknown. This study aimed to correlate levels of IL-10 with its receptor expression in newly diagnosed T2DM cases and compare the findings with that of a non-diabetic control group. 35 newly diagnosed T2DM and 35 non-diabetic controls were recruited after obtaining due informed consent. Venous blood was taken under aseptic conditions. Biochemical parameters were analyzed in an autoanalyzer. Serum levels of IL-10 were estimated using ELISA, and IL-10R expression was estimated using RT-PCR by TaqMan Advanced gene expression assay. Serum levels of IL-10 were significantly lowered in T2DM patients (10.93 (8.62) pg/ml) compared with non-diabetic controls (14.52 (9.71) pg/ml) (p < 0.015). IL-10R expression was significantly downregulated in T2DM patients with a fold change of 0.18 (p < 0.018). Our study suggests that the expression of IL-10R is downregulated along with low serum levels of IL-10 in newly diagnosed Type 2 diabetes mellitus patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
